Page 291«..1020..290291292293..300310..»

Category Archives: Stem Cells

The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014

Posted: June 24, 2012 at 3:59 pm


The California stem cell agency's
leading efforts to find a cure for HIV – one tied to the famous "Berlin Patient" – received a plug today in a piece in the
state capital's largest circulation newspaper, The Sacramento Bee.

The article by David Lesher focused on
a $14 million CIRM grant to the City of Hope in Los Angeles that also
involves Sangamo BioSciences of Richmond, Ca. The team hopes to
launch a clinical trial by the end of next year.
The Berlin Patient is Timothy Brown,
now of San Francisco, who is the only person in the world known to
have been cured of HIV/AIDs. It came about as a side effect of a
blood transfusion carrying a rare mutation of a gene found almost
entirely among northern Europeans. Lesher, director of governmental
affairs for the Public Policy Institute in Sacramento, wrote,

"The
possibility of curing a global pandemic like AIDS with funding from
the California bond is exactly the kind of exciting potential that
inspired voters to approve Proposition 71
 by
a wide margin. But the HIV research is also a good example of the
challenge facing the state's s
tem cell agency
as it tries to show voters that they made a good investment.
 

None
of the research under way will reach patients until long after the 10
years of funding by the ballot measure runs out. With the HIV
project, researchers hope to be in human trials by 2014, but it is
likely to be at least 10 years before they can show it might work in
humans. And in the case of a stem cell
 cure
for AIDS, it would be many years after that before a treatment is
widely available.”

Jeff
Sheehy
, a prominent AIDS activist and a board member at the 
stem
cell
 agency,
described the effort as "the global home run. That's not in 10
years. … But this could be the beginning of something really
amazing."
Lesher also wrote,

"Nobody
thought stem cells 
might
be used to cure HIV when the bond (funding for the stem cell agency)
passed. Far from the embryonic stem cell 
treatments
that inspired the ballot measure, the HIV research involves a new and
growing integration of stem cell 
and
genetic science."

Indeed,
the ballot initiative that created the $3 billion California stem
cell agency trumpeted its devotion to human embryonic stem cell
research, which had been throttled by the Bush Administration. The
agency has veered away from hESC research, which now amounts
to less than $450 million out of the $1.4 billion in grants approved
since 2004. 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014

Parsing Geron's Stem Cell Foray: A Nature Journal Commentary

Posted: June 24, 2012 at 3:57 pm


Why did Geron "fail" in its
much ballyhooed pursuit of the first-ever human embryonic stem cell
therapy?

Christopher Scott, senior
research scholar at Stanford, and Brady Huggett,
business editor of the journal Nature, took a crack at
answering that question in a commentary in the June edition of
Nature.
Following the sudden abandonment last
fall by Geron of its hESC business and the first-ever clinical trial
of an hESC therapy, Scott and Huggett scrutinized the history of the
company. The financial numbers were impressive. They wrote,

"How did Geron’s R&D program
meet such a demise? After all, the company raised more than $583
million through 23 financings, including two venture rounds, and
plowed more than half a billion dollars into R&D (about half of
that into hESC work) through 2010. 

"There are problems with being at
the forefront of unknown territory. Of Geron’s development efforts,
the hESC trial was the most prominent, and fraught. Therapies based
on hESCs were new territory for the US Food and Drug
Administration
(FDA), and it eyed Geron warily. The
investigational new drug application (IND), filed in 2008, was twice
put on clinical hold while more animal data were collected among
fears that nonmalignant tumors would result from stray hESCs that
escaped the purification process. Geron says it spent $45 million on
the application, and at 22,000 pages, it was reportedly the largest
the agency had ever received."

The California stem cell agency also
bet $25 million on the company just a few months before it pulled the
plug. Geron repaid all the CIRM money that it had used up to that point.
Geron suffered from a lack of revenue
despite its vaunted stem cell patent portfolio. Scott and Huggett
reported that Geron received only $69 million from 1992 to 2010 from
collaborations, license and royalties. At the same time losses were
huge – $111 million in 2010.
The Nature article noted all of that
was occurring while other biotech companies – such as Isis
and Alnylam – found ample financial support, revenue and
success.
Scott's and Huggett's directed their
final comment to Advanced Cell Technology, now the only
company in the United States with a clinical trial involving a human
embryonic stem cell therapy.

"Your technology may be
revolutionary, your team may be dedicated and you may believe. But it
does not matter if no one else will stand at your side."

Our take: The California stem cell
agency obviously has learned something from its dealings with Geron.
The company's hESC announcement was an unpleasant surprise, to put it
mildly, coming only about three months after CIRM signed the Geron
loan agreement. Today, however, the agency has embarked on more,
equally risky ventures with other biotech enterprises. Indeed, CIRM
is forging into areas that conventional investment shuns. It is all
part of mission approved by California voters in 2004.
The dream of cures from human embryonic
stem cells or even adult stem cells is alluring. And CIRM is feeling
much justifiable pressure to engage industry more closely. All the
more reason for CIRM's executives and directors to maintain a steely
determination to terminate research programs that are spinning their
wheels and instead pursue efforts that are making significant
progress in commercializing research and attracting other investors.  

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Parsing Geron's Stem Cell Foray: A Nature Journal Commentary

The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014

Posted: June 24, 2012 at 3:56 pm


The California stem cell agency's
leading efforts to find a cure for HIV – one tied to the famous "Berlin Patient" – received a plug today in a piece in the
state capital's largest circulation newspaper, The Sacramento Bee.

The article by David Lesher focused on
a $14 million CIRM grant to the City of Hope in Los Angeles that also
involves Sangamo BioSciences of Richmond, Ca. The team hopes to
launch a clinical trial by the end of next year.
The Berlin Patient is Timothy Brown,
now of San Francisco, who is the only person in the world known to
have been cured of HIV/AIDs. It came about as a side effect of a
blood transfusion carrying a rare mutation of a gene found almost
entirely among northern Europeans. Lesher, director of governmental
affairs for the Public Policy Institute in Sacramento, wrote,

"The
possibility of curing a global pandemic like AIDS with funding from
the California bond is exactly the kind of exciting potential that
inspired voters to approve Proposition 71
 by
a wide margin. But the HIV research is also a good example of the
challenge facing the state's s
tem cell agency
as it tries to show voters that they made a good investment.
 

None
of the research under way will reach patients until long after the 10
years of funding by the ballot measure runs out. With the HIV
project, researchers hope to be in human trials by 2014, but it is
likely to be at least 10 years before they can show it might work in
humans. And in the case of a stem cell
 cure
for AIDS, it would be many years after that before a treatment is
widely available.”

Jeff
Sheehy
, a prominent AIDS activist and a board member at the 
stem
cell
 agency,
described the effort as "the global home run. That's not in 10
years. … But this could be the beginning of something really
amazing."
Lesher also wrote,

"Nobody
thought stem cells 
might
be used to cure HIV when the bond (funding for the stem cell agency)
passed. Far from the embryonic stem cell 
treatments
that inspired the ballot measure, the HIV research involves a new and
growing integration of stem cell 
and
genetic science."

Indeed,
the ballot initiative that created the $3 billion California stem
cell agency trumpeted its devotion to human embryonic stem cell
research, which had been throttled by the Bush Administration. The
agency has veered away from hESC research, which now amounts
to less than $450 million out of the $1.4 billion in grants approved
since 2004. 

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Posted in Stem Cells, Stem Cell Therapy | Comments Off on The California Stem Cell Agency and an HIV Cure: Pushing for a Clinical Trial in 2014

Scientists grow tiny liver in mouse’s head

Posted: June 22, 2012 at 9:24 am

Using stem cells from human skin, Japanese scientists have grown a small human liver inside the skull of a mouse.

Hideki Taniguchi and Takanori Takebe from Yokohama City University used stem cells generated from human skin cells and developed them into percussor liver cells, the New Scientist reports.

Then they added other cells from umbilical cord blood vessels. The combination of cells then "guided itself" to form a small structure similar to liver tissue, Takebe said.

"We mixed and graded the cells onto the culture dish and they moved to form a cluster," he said. "It was a surprising outcome from what was, to be honest, an accident."

They implanted the structure into the head of a mouse, which was suffering from a severe genetic immune system disorder that prevented it from having an immune reaction to the foreign tissues.

The increased blood flow in the mouse's skull allowed the tissue to keep growing.

Within 48 hours, human blood vessels and human proteins formed. Glycogen and amino acids levels were the same as those of a human liver.

"It's not yet a perfect liver," Takebe said. "Improvements need to be made, such as the reconstruction of a bile duct."

The study could be significant for the field of regenerative medicine, but the researchers aren't yet sure whether the organ is a fully functioning liver, or whether they will be able to scale it to human size.

The findings were presented at the at the International Society for Stem Cell Research's annual meeting in Yokohama.

See the original post here:
Scientists grow tiny liver in mouse's head

Posted in Stem Cells | Comments Off on Scientists grow tiny liver in mouse’s head

SPIONs to Track Functioning of Stem Cells Inside Body

Posted: June 22, 2012 at 9:24 am

Have you ever wondered what happens to the stem cells once it is implanted in our body?

Well, now scientists had developed a method to track the stem cells in our body, according to a new report.

Scientists from the University of Liverpool have developed new methods to track stem cells and the changes that happen to them after they have been in the body for a significant period of time.

Scientists "labeled" the cells with superparamagnetic iron oxide nanoparticles (SPIONs) before they were administered to the patients.

The magnetic resonance imaging (MRI) scans clearly showed movement of the stem cells and the scientists could determine whether the stem cells reached their intended target or not.

However, scientists warn that conditions within the body's cells can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Like us on Facebook

To overcome this drawback, scientists are developing new methods to visualise SPION's in the cells before they enter the body to learn their performance in the long-term.

Photothermal technique, a unique optical imaging system is used to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body," said Dr Lara Bogart, scientist at the University's Institute of Integrative Biology in a statement.

The rest is here:
SPIONs to Track Functioning of Stem Cells Inside Body

Posted in Stem Cells | Comments Off on SPIONs to Track Functioning of Stem Cells Inside Body

Research could help track stem cells in the body

Posted: June 21, 2012 at 7:13 pm

Public release date: 21-Jun-2012 [ | E-mail | Share ]

Contact: Samantha Martin samantha.martin@liv.ac.uk 044-015-179-42248 University of Liverpool

Researchers at the University of Liverpool have developed new methods to track stem cells and further understanding of what happens to them after they have been in the body for a significant period of time.

Stem cells are used to treat conditions such as leukaemia and have the potential to treat many more diseases and disorders where patient survival is reliant on organ and tissue donation. Currently, however, it is difficult for medics to establish whether stem cells have survived following transplantation in the body and if they reach their target site or migrate elsewhere.

In order to track stem cells in the body scientists use superparamagnetic iron oxide nanoparticles (SPIONs) to 'label' the cells before they are administered into the patient. These particles can be picked up by magnetic resonance imaging (MRI) scans and help medics establish if the stem cells reach their intended target. Conditions within the body's cells, however, can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Scientists at Liverpool are developing methods to visualise SPIONs in the cells before they enter the body to learn where the particles are going within the stem cell and help predict how they might perform once they are inside the body over a long period of time. They are using a photothermal technique, a unique optical imaging system, to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

Dr Lara Bogart, from the University's Institute of Integrative Biology, said: "Stem cells have the potential to replace and repair damaged tissue to preclude the need for a patient to wait for an organ or tissue transplant. Research is ongoing into how it could be used to treat a wide variety of diseases such as Alzheimer's, Parkinson's disease, and type one diabetes.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body.

"Labelling stem cells is hugely valuable to tracking their movements in the body, but we need to know more about how the particles used interact with stem cells. Using new imaging systems we can work out their precise location in the cell and how they behave over time. We hope to use this information to improve understanding of the MRI signal that tracks SPIONs once stem cells have been transplanted."

###

Excerpt from:
Research could help track stem cells in the body

Posted in Stem Cells | Comments Off on Research could help track stem cells in the body

Superparamagnetic iron oxide nanoparticles could help track stem cells in the body

Posted: June 21, 2012 at 7:13 pm

Researchers at the University of Liverpool have developed new methods to track stem cells and further understanding of what happens to them after they have been in the body for a significant period of time.

Stem cells are used to treat conditions such as leukaemia and have the potential to treat many more diseases and disorders where patient survival is reliant on organ and tissue donation. Currently, however, it is difficult for medics to establish whether stem cells have survived following transplantation in the body and if they reach their target site or migrate elsewhere.

In order to track stem cells in the body scientists use superparamagnetic iron oxide nanoparticles (SPIONs) to 'label' the cells before they are administered into the patient. These particles can be picked up by magnetic resonance imaging (MRI) scans and help medics establish if the stem cells reach their intended target. Conditions within the body's cells, however, can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Scientists at Liverpool are developing methods to visualise SPIONs in the cells before they enter the body to learn where the particles are going within the stem cell and help predict how they might perform once they are inside the body over a long period of time. They are using a photothermal technique, a unique optical imaging system, to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

Dr Lara Bogart, from the University's Institute of Integrative Biology, said: "Stem cells have the potential to replace and repair damaged tissue to preclude the need for a patient to wait for an organ or tissue transplant. Research is ongoing into how it could be used to treat a wide variety of diseases such as Alzheimer's, Parkinson's disease, and type one diabetes.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body.

"Labelling stem cells is hugely valuable to tracking their movements in the body, but we need to know more about how the particles used interact with stem cells. Using new imaging systems we can work out their precise location in the cell and how they behave over time. We hope to use this information to improve understanding of the MRI signal that tracks SPIONs once stem cells have been transplanted."

More information: The research is published in the journal, ACS Nano.

Journal reference: ACS Nano

Provided by University of Liverpool

Read this article:
Superparamagnetic iron oxide nanoparticles could help track stem cells in the body

Posted in Stem Cells | Comments Off on Superparamagnetic iron oxide nanoparticles could help track stem cells in the body

StemCells, Inc. Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

Posted: June 21, 2012 at 7:13 pm

NEWARK, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD) referred to as Geographic Atrophy. There are no approved treatments for dry AMD.

The trial is being conducted at the Retina Foundation of the Southwest's (RFSW) Anderson Vision Research Center in Dallas, Texas, one of the leading independent vision research centers in the United States. David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, is the principal investigator of the study.

"Dry AMD is the most common form of macular degeneration, and has a very debilitating effect on quality of life," said Dr. Birch. "Transplanting neural stem cells to protect photoreceptors in patients diagnosed with AMD is an innovative, but logical, approach, well supported by the Company's recently published preclinical data. We are very excited to be conducting this trial at RFSW."

A summary of the Company's preclinical data was featured in the February 2012 issue of the international peer-reviewed European Journal of Neuroscience (available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract). The data demonstrated that HuCNS-SC cells protect host photoreceptors and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease which has been used extensively to evaluate potential cell therapies. Transplantation of HuCNS-SC cells significantly protects photoreceptors from degeneration. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors accounts for the unique pattern of vision loss in dry AMD.

"Unlike others in the field, our clinical strategy is to preserve visual function before it is lost," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Our published preclinical data provides a strong rationale for this approach in dry AMD and we hope to replicate these results in this clinical trial. We are very pleased to be working with Dr. Birch and the Retina Foundation of the Southwest, who have the expertise and referral base to undertake this important study. We anticipate that we will be able to accrue the requisite number of patients for this trial in relatively short order."

About Age-Related Macular Degeneration

Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. AMD is a degenerative retinal disease that typically strikes adults in their 50s or early 60s, and progresses painlessly, gradually destroying central vision. According to the RFSW website, there are approximately 1.75 million Americans age 40 years and older with some form of age-related macular degeneration, and the disease continues to be the number one cause of irreversible vision loss among senior citizens in the US with more than seven million at risk of developing AMD.

About the Trial

The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina in the most affected eye. Patients' vision will be evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations will be performed at predetermined intervals over a one-year period to assess safety and signs of visual benefit. Patients will then be followed for an additional four years in a separate observational study. Patients interested in participating in the clinical trial should contact the site at (214) 363 3911.

About HuCNS-SC Cells

Read the original post:
StemCells, Inc. Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

Posted in Stem Cells | Comments Off on StemCells, Inc. Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

Stem Cells To Aid In Heart-Related Research

Posted: June 21, 2012 at 7:13 pm

June 21, 2012

Connie K. Ho for redOrbit.com

Pumping vigorously night and day, the heart is clearly one of the most important organs in the human body. It is also one of the most delicate parts of the body. As such, news regarding heart-related diseases is beneficial to both doctors and patients. University of Michigan (UM) researchers recently reported the discovery of a new method that could produce cardiac muscle patches from stem cells.

The innovative process was created at UMs Center for Arrhythmia Research and effectively uses stem cells that can copy the hearts squeezing action. The cells showed activity that was like that of peoples resting heart rate. The rhythmic electrical impulse transmission of the engineered cells worked at a rate of 60 beats per minute and this rate was 10 times quicker than rates reported in other stem cell studies.

To date, the majority of studies using induced pluripotent stem cell-derived cardiac muscle cells have focused on single cell functional analysis, remarked senior author Dr. Todd J. Herron, an assistant research professor in the Departments of Internal Medicine and Molecular & Integrative Physiology at the U-M, in a prepared statement.

The researchers believe that the stem biology findings will be beneficial to those who suffer from common but life-threatening heart diseases. They hope that the use of stem cells will assist patients diagnosed with arrhythmia, which is found in approximately 2.5 million people. With arrhythmia, patients suffer an irregularity in the hearts electrical impulses and this can hinder the hearts ability to circulate blood.

For potential stem cell-based cardiac regeneration therapies for heart disease, however, it is critical to develop multi-cellular tissue like constructs that beat as a single unit, commented Herron in the statement.

Regarding the specifics of the project, the goal of the scientists was to use stem cells to develop skin biopsies. These biopsies could be used to produce large quantities of cardiac muscle cells, which could then help transmit uniform electrical impulses and work as a cohesive unit. In collaborating with researchers from the University of Oxford, Imperial College, and the University of Wisconsin, the team was able to design a fluorescent imaging platform. The platform used light emitting diode (LED) illumination to quantify the cells electrical activity.

Action potential and calcium wave impulse propagation trigger each normal heart beat, so it is imperative to record each parameter in bioengineered human cardiac patches, remarked Herron in the statement.

Overall, authors of the study believe that the velocity of the engineered cardiac cells is still slower than the velocity of cells found in the beating adult heart. However, the velocity of the engineered cardiac cells is quicker than those previously reported; it is also similar to the rate found in commonly used rodent cells. For future scientific research purposes, the investigators theorize that human cardiac patches could be utilized instead of rodent systems. The new method could be used in many cardiac research laboratories and allow cardiac stem cell patches to be utilized in disease research, new drug treatment testing, and therapies focused on repairing damaged heart muscles.

Read more:
Stem Cells To Aid In Heart-Related Research

Posted in Stem Cells | Comments Off on Stem Cells To Aid In Heart-Related Research

Tracking stem cells in the body

Posted: June 21, 2012 at 7:13 pm

ScienceDaily (June 21, 2012) Researchers at the University have developed new methods to track stem cells and further understanding of what happens to them after they have been in the body for a significant period of time.

Stem cells are used to treat conditions such as leukemia and have the potential to treat many more diseases and disorders where patient survival is reliant on organ and tissue donation. Currently, however, it is difficult for medics to establish whether stem cells have survived following transplantation in the body and if they reach their target site or migrate elsewhere.

In order to track stem cells in the body scientists use superparamagnetic iron oxide nanoparticles (SPIONs) to 'label' the cells before they are administered into the patient. These particles can be picked up by magnetic resonance imaging (MRI) scans and help medics establish if the stem cells reach their intended target. Conditions within the body's cells, however, can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Scientists at Liverpool are developing methods to visualise SPIONs in the cells before they enter the body to learn where the particles are going within the stem cell and help predict how they might perform once they are inside the body over a long period of time. They are using a photothermal technique, a unique optical imaging system, to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

Effective monitoring

Dr Lara Bogart, from the University's Institute of Integrative Biology, said: "Stem cells have the potential to replace and repair damaged tissue to preclude the need for a patient to wait for an organ or tissue transplant. Research is ongoing into how it could be used to treat a wide variety of diseases such as Alzheimer's, Parkinson's disease, and type one diabetes.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body.

"Labelling stem cells is hugely valuable to tracking their movements in the body, but we need to know more about how the particles used interact with stem cells. Using new imaging systems we can work out their precise location in the cell and how they behave over time. We hope to use this information to improve understanding of the MRI signal that tracks SPIONs once stem cells have been transplanted."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

More:
Tracking stem cells in the body

Posted in Stem Cells | Comments Off on Tracking stem cells in the body

Page 291«..1020..290291292293..300310..»